Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATIVAN vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
30-35% bound to albumin.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
Oral: 70-85% with high variability; intrathecal: 100%.
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
No specific food interactions. Avoid alcohol due to additive CNS depression.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATIVAN vs BACLOFEN, answered by our medical review team.
ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATIVAN and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATIVAN and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.